MIRA Pharmaceuticals Inc. Common Stock (MIRA)
FairStock Score: 20/100 — RISKY
Key Financials
| Current Price | $0.62 |
| Market Cap | $26M |
| P/E Ratio | -0.51 |
| ROE | -217.12% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I am wary of businesses that cannot yet produce earnings, and MIRA Pharmaceuticals fits that description. It is a pre-clinical-stage neuroscience company with no revenue reported in filed figures for fiscal year 2023, the year ended 2023-12-31; fiscal year 2024, the year ended 2024-12-31; and fiscal year 2025, the year ended 2025-12-31. It lost $12.0 million in fiscal year 2023, $7.9 million in fiscal year 2024, and $10.4 million in fiscal year 2025. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported a net loss of $1.2 million and diluted EPS of -$0.03. Trailing free cash flow was -$4.6 million, and the FairStock FCF yield is -16.6%. Those are not the marks of a durable business with a moat; they are the marks of a cash-consuming research effort whose value depends on future clinical success.
In plain English: MIRA is a small drug development company with no product sales yet. It has been losing money and burning cash while testing experimental medicines for brain and mental health conditions. At $0.67, the price may look low, but because there are no profits or revenue, it is hard to call it cheap based on the numbers; it looks speculative.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer